Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs TG 4010 (Primary) ; Nivolumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Mar 2018 According to a Transgene media release, results from the interim analysis of this study are expected in 2H 2018.
- 13 Sep 2017 According to a Transgene media release, first results from this trial are expected in the beginning of 2018.
- 13 Mar 2017 According to a Transgene media release, first results from the study could be expected from the end of 2017.